Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma.
复制标题
B7-H3的肿瘤细胞和肿瘤脉管表达预测透明细胞肾细胞癌的存活。
DOI：
10.1158/1078-0432.ccr-08-0536
复制
发表时间：
2008-08-15
期刊：
影响因子：
--
通讯作者：
Kwon ED
中科院分区：
文献类型：
--
作者：
Crispen PL;Sheinin Y;Roth TJ;Lohse CM;Kuntz SM;Frigola X;Thompson RH;Boorjian SA;Dong H;Leibovich BC;Blute ML;Kwon ED
尽管透明细胞肾细胞癌 (ccRCC) 中肿瘤细胞表达 B7-H1 和 B7-H4 的预后价值已确定，但 B7-H3 的作用尚不清楚。因此，我们评估了接受 ccRCC 治疗的患者中 B7-H3 表达与临床病理结果的关联。通过免疫组织化学染色评估了 1990 年至 1999 年在我们机构接受 ccRCC 治疗的 743 名连续患者的肾切除标本中的 B7-H3 表达。使用 χ2 和 Fisher 精确检验评估 B7-H3 表达与临床和病理特征的关联。使用 Cox 比例风险回归模型评估 B7-H3 表达与 RCC 死亡的关联。分别在 17% 和 95% 的样本中发现肿瘤细胞或肿瘤脉管系统表达 B7-H3。 46% 的标本中存在 B7-H3 的肿瘤细胞或弥漫性肿瘤脉管系统表达，并且与多种不良临床和病理特征相关。经过多变量调整后，肿瘤细胞或弥漫性肿瘤脉管系统 B7-H3 表达的存在与 RCC 死亡风险增加显着相关（风险比，1.38；95% 置信区间，1.03-1.84；P = 0.029）。肿瘤细胞和肿瘤脉管系统 B7-H3 表达都传达了预测 ccRCC 结果的重要信息。总的来说，我们过去和现在有关 B7-H 配体表达的研究表明 ccRCC 可能使用冗余机制来损害宿主抗肿瘤免疫。未来的研究将集中于 B7-H 配体联合表达对 RCC 的影响。
Although the prognostic value of B7-H1 and B7-H4 expression by tumor cells in clear cell renal cell carcinoma (ccRCC) has been established, the role of B7-H3 is unknown. As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC. Nephrectomy specimens from 743 consecutive patients treated for ccRCC at our institution from 1990 to 1999 were evaluated for B7-H3 expression by immunohistochemical staining. Associations of B7-H3 expression with clinical and pathologic features were evaluated using χ2 and Fisher's exact tests. Associations of B7-H3 expression with death from RCC were evaluated using Cox proportional hazards regression models. B7-H3 expression by tumor cells or tumor vasculature was noted in 17% and 95% of specimens, respectively. The presence of either tumor cell or diffuse tumor vasculature expression of B7-H3 was present in 46% of specimens and was associated with multiple adverse clinical and pathologic features. After multivariable adjustment, the presence of either tumor cell or diffuse tumor vasculature B7-H3 expression was significantly associated with an increased risk of death from RCC (risk ratio, 1.38; 95% confidence interval, 1.03-1.84; P = 0.029). Both tumor cell and tumor vasculature B7-H3 expression convey important information to predict ccRCC outcomes. Collectively, our past and present studies pertaining to B7-H ligand expression indicate that ccRCC may use redundant mechanisms to compromise host antitumoral immunity. Future studies will focus on the effect of combined B7-H ligand expression in RCC.